摘要目的 评估血清胸苷激酶1(STK1)在健康体检人群中的临床应用价值.方法 选取健康体检人群8896例,采用高灵敏度点印染/免疫增强发光检测系统(ECL)进行STK1浓度测定,同时与常规体检平行进行.结果 以2 pmol/L为阈值,阳性组STK1水平为(5.47±4.23)pmol/L,明显高于阴性组(0.62±0.48)pmol/L(t=11.90,P=0.00).STK1水平高低无性别相关性,但与年龄老化有关,STK1阳性组平均年龄(48.2±12.0)岁,STK1阴性组平均年龄(41.8±12.3)岁(t=5.37,P=0.00).STK1阳性率为1.2％(108/8896),其中疾病包括:恶性肿瘤治疗前/后1.9％,癌前病变/良性肿瘤27.8％,非肿瘤增殖性疾病36.0％,乙型肝炎(乙肝)/幽门螺旋杆菌(HP)感染14.8％,脂肪肝10.2％,其他疾病占9.3％,与肿瘤没有直接或间接联系,STK1预示可能渐变为癌症的风险为90.7％.STK1阴性组未筛查出恶性肿瘤和癌前病变,而恶性肿瘤治疗后、良性肿瘤、非肿瘤增殖性疾病在与STK1阳性组相应疾病比较中,差异均有统计学意义(P＜0.05).结论 STK1能真实评估体内细胞异常增殖情况,适用于体检人群早期肿瘤风险筛查.对于STK1阳性者,需对导致STK1增高的其他非肿瘤因素进行排查,同时体检者要定期监测,以便尽可能给予预防治疗和早期诊断.

abstractsObjective To evaluate the utility of serum thymidine kinase 1(STK1)in health screening.Methods A total of 8896 adults who participated in health check-up during November 2009 and November 2010 were tested for STK1 by using sensitive chemiluminescence's dot blot assay.Results The level of STK1 of group A(STK1 ＞ 2 pmol/L)was much higher than that of the group B(STK1 ＜ 2 pmol/L)[(5.47 ±4.23)vs(0.62 ±0.48)pmol/L;t =11.90,P =0.00].The STK1 level was not correlated with gender.However,the mean age of individuals in the group A was higher than that in the group B[(48.2 ± 12.0)vs(41.8 ± 12.3)years; t =5.37,P =0.00].The positive detection rate of STK1 was 1.2％(108/ 8896).In the group A,there were 1.9％ pre-or post-treatment malignancy,27.8％ pre-malignant tumor or benign disease,36.0％ nontumorous proliferation disease,14.8％ hepatitis B virus/HP infection,10.2％fatty liver,and 9.3％ other diseases.No pre-treatment malignancy and pre-malignancy were found in the group B.Conclusion STK1 measurement could reflect the situation of cell proliferation and predict the risk of any type of malignancy.